Rofapitide tetraxetan (acetate)
Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity[1].
Product Specifications
Product Name Alternative
FAP-2286 (acetate)
UNSPSC
12352005
Target
FAP
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fap-2286-acetate.html
Solubility
10 mM in DMSO
Smiles
O=C(N1[C@@](C(N[C@@](C(N[C@H](C(N[C@H](C2=O)CC3=CC=CC=C3)=O)CCC(N)=O)=O)([H])[C@H](O)C)=O)([H])CCC1)[C@@](CCC4)([H])N4C([C@H](CSCC5=CC(CSCCNC(CN(CCN(CC6)CC(O)=O)CCN(CCN6CC(O)=O)CC(O)=O)=O)=CC(CSC[C@H](N2)C(O)=O)=C5)NC(CCCCC)=O)=O.CC(O)=O
Molecular Formula
C69H103N13O20S3
Molecular Weight
1530.83
References & Citations
[1]Baum RP, et al. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results. J Nucl Med. 2022 Mar;63 (3) :415-423.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940718-500 1x 500 µL
HER-2 / CD340 (HRB2/718), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC742468-100 1x 100 µL
Perforin-1 (Pore Forming Protein) (Apoptosis Marker) (PRF1/2468), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
